Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Heron Therapeutics (HRTX) Assets Average: 2011-2025

Historic Assets Average for Heron Therapeutics (HRTX) over the last 12 years, with Sep 2025 value amounting to $240.5 million.

  • Heron Therapeutics' Assets Average rose 9.60% to $240.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $240.5 million, marking a year-over-year increase of 9.60%. This contributed to the annual value of $227.8 million for FY2024, which is 3.76% down from last year.
  • According to the latest figures from Q3 2025, Heron Therapeutics' Assets Average is $240.5 million, which was up 2.82% from $233.9 million recorded in Q2 2025.
  • Heron Therapeutics' 5-year Assets Average high stood at $378.3 million for Q3 2021, and its period low was $211.1 million during Q2 2023.
  • Its 3-year average for Assets Average is $225.6 million, with a median of $225.9 million in 2023.
  • As far as peak fluctuations go, Heron Therapeutics' Assets Average tumbled by 33.00% in 2021, and later grew by 9.60% in 2025.
  • Heron Therapeutics' Assets Average (Quarterly) stood at $329.0 million in 2021, then fell by 20.54% to $261.5 million in 2022, then fell by 13.62% to $225.9 million in 2023, then climbed by 0.49% to $227.0 million in 2024, then grew by 9.60% to $240.5 million in 2025.
  • Its Assets Average was $240.5 million in Q3 2025, compared to $233.9 million in Q2 2025 and $234.4 million in Q1 2025.